Biotech executives convene under Vir Biotechnology leadership to drive innovation at BIO2026

Biotech executives convene under Vir Biotechnology leadership to drive innovation at BIO2026
Vir Biotechnology leads BIO2026 kickoff

Marianne De Backer, CEO of Vir Biotechnology, joined fellow members of the IAmBiotech Board of Directors to kick off BIO2026.

The event brings together leading figures from the biotech ecosystem to explore new ways to advance innovation in the U.S., with a focus on enhancing the delivery of meaningful treatments for patients. De Backer's participation reflects a strategic effort to foster industry collaboration and shape the future of biotechnology.

Vir Biotechnology has recently shared early Phase 1 data for VIR-5500 in metastatic prostate cancer and expanded its collaboration with Astellas at ASCO2026. The company also presented data at EASL2026 on the impact of BMI on ALT normalization in chronic hepatitis delta patients from the Phase 2 SOLSTICE study. These developments reflect Vir's ongoing focus on advancing clinical research across multiple indications.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.